Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Evotec AG

Apr 2010
Evotec AG of Hamburg, Germany, has announced that it is collaborating with Active Biotech AB to identify small-molecule modulators of a priority biological target involved in immune disorders and cancer. The former, a drug discovery company, will use its technologies in assay development and high-throughput and surface plasmon resonance screening to identify and validate novel hits. It will screen its Lead Discovery Library, a small-molecule collection, to maximize the probability of finding medicinal chemistry starting points. Active Biotech of Lund, Sweden, develops pharmaceuticals for diseases of the immune system.

See acousto-optic modulator; electro-optic modulator.
Active BiotechBasic SciencebiologicalBiophotonicsBusinesscancercollaborationdiseasedrug discoveryEuropeEvotec AGGermanyimmune disorderimmune systemLead Discovery LibrarymodulatorpharmaceuticalsRapidScanscreeningsmall-molecule modulatorssurface plasmon resonance screeningSweden

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,
x Subscribe to BioPhotonics magazine - FREE!